论文部分内容阅读
本文研制了炎痛喜康控释片,其体外溶出行为符合一级动力学过程,讨论了相关试验条件对体外溶出度的影响。服用炎痛喜康制剂后体内血浓用HPLC测定,其体内配置状态符合单室药动学模型,经计算机模型嵌合处理求得药动学参数,控释片(A)相对于普通片(B)的生物利用度为100.5%,体内外相关关系结果表明:体内吸收分数与累积释药百分率之间有较好的线性相关关系。与普通片相比,控释片对家兔胃的急性刺激性明显降低。
In this paper, we developed Yan Tong Kang Kang controlled release tablets, in vitro dissolution behavior in line with the first-order kinetic process, discussed the impact of relevant test conditions on in vitro dissolution. After taking YKK, the blood concentration in the body was determined by HPLC. The in vivo configuration was in accordance with the single-compartment pharmacokinetic model. The pharmacokinetic parameters were obtained by the chimeric treatment of the computer model. The controlled release tablets (A) The bioavailability of B was 100.5%. The correlation between in vivo and in vitro results showed that there was a good linear correlation between the in vivo absorption fraction and the cumulative release percentage. Compared with ordinary tablets, controlled release tablets on the rabbit stomach acute irritation was significantly reduced.